PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy

• Published in: Journal of cellular physiology Vol. 234; no. 2; pp. 1313 - 1325
• Main Authors: Dermani, Fatemeh K., Samadi, Pouria, Rahmani, Golebagh, Kohlan, Alisa K., Najafi, Rezvan
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2019
• Subjects: Animals; Anticancer properties; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antitumor activity; Apoptosis; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; Cancer; Cancer therapies; Cell death; Dendritic cells; Humans; Immune checkpoint; immune checkpoints; Immunity; Immunotherapy - adverse effects; Immunotherapy - methods; Ligands; Lymphocytes; Lymphocytes B; Lymphocytes T; Molecular Targeted Therapy; Natural killer cells; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - pathology; PD-L1 protein; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Programmed Cell Death 1 Receptor - metabolism; programmed cell death protein 1 (PD‐1); programmed death ligand 1 (PD‐L1); Proteins; Signal Transduction; Treatment Outcome; Tumor cells; Tumor Escape; Tumor Microenvironment; Tumors; cancer; programmed death ligand 1 (PD-L1); programmed cell death protein 1 (PD-1); immune checkpoints

Recent studies show that cancer cells are sometimes able to evade the host immunity in the tumor microenvironment. Cancer cells can express high levels of immune inhibitory signaling proteins. One of the most critical checkpoint pathways in this system is a tumor‐induced immune suppression (immune c...